The results and conclusions of the work conducted by the Lymphoma Research Experts ecosystem are published in leading medical journals.
Lysa
2022_LYSA_Chapter 22: Bridging Chemotherapy: Relapsed/Refractory Aggressive B-Cell Lymphoma
DOI: 10.1007/978-3-030-94353-0_22
Learn more
Lysa
2022_LYSA_Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma
DOI: 10.1097/HS9.0000000000000675
Learn more
Lysa
2022_LYSA_What Prognostic Markers Should Be Evaluated in Marginal Zone Lymphoma? A Survey Among Leading International Experts
DOI: 10.1097/HS9.0000000000000680
Learn more
Lysa
2022_LYSA_PET imaging: back in the game for gastric EMZL?
doi: 10.1182/blood.2021013964.
Learn more
Lysa
2022_LYSA_Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study
J Clin Oncol 2022 Jan 6;JCO2101777. doi: 10.1200/JCO.21.01777
Learn more
Lysa
2022_LYSA_Obinutuzumab plus lenalidomide (GALEN) in advanced, previously untreated follicular lymphoma in need of systemic therapy
Blood . 2022 Apr 14;139(15):2338-2346.
Learn more
Lysa
2021_LYSA_The landscape of copy number variations in classical Hodgkin lymphoma: a joint KU Leuven and LYSA study on cell-free DNA
Blood Advances 2021
Learn more
Lysa
2021_LYSA_Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides linger disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from LyMA prospective trial
Bone Marrow Transplant . 2021 Jul;56(7):1700-1709.
Learn more
Lysa
2021_LYSA_Adverse outcome in follicular lymphoma is associated with MYC rearrangements but not MYC extra copies
Br J Haematol . 2021 Jul;194(2):382-392.
Learn more
Lysa
2021_LYSA_Extracellular vesicles shed by follicular lymphoma B cells promote polarization of the bone marrow stromal cell niche
Blood . 2021 Jul 8;138(1):57-70.
Learn more
Lysa
2021_LYSA_Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP
Blood Adv . 2021 Aug 10;5(15):2965-2968.
Learn more
Lysa
2021_LYSA_High-grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular Diversity Extending Beyond Grades 3A and 3B
Am J Surg Pathol . 2021 Oct 1;45(10):1324-1336.
Learn more
Lysa
2021_LYSA_Outcomes after first-line immunochemotherapy for primary mediastinal B cell lymphoma patients: a LYSA study
Blood Adv . 2021 Oct 12;5(19):3862-3872.
Learn more
Lysa
2021_LYSA_Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011)
J Clin Oncol . 2021 Oct 10;39(29):3251-3260.
Learn more
Lysa
2021_LYSA_Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumor volume prediction using a convolutional neural network
Eur J Nucl Med Mol Imaging . 2021 May;48(5):1362-1370. doi: 10.1007/s00259-020-05080-7.
Learn more
Lysa
2021_LYSA_Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA
Blood . 2021 Apr 29;137(17):2307-2320. doi: 10.1182/blood.2020008750.
Learn more
Lysa
2021_LYSA_Lenalidomide tiggers T-cell effector functions in vivo in patients with follicular lymphoma
Blood Adv . 2021 Apr 27;5(8):2063-2074.
Learn more
Lysa
2021_LYSA_Sub-Cutaneous Rituximab-MiniCHOP compared to Sub-Cutaneous Rituximab-MiniCHOP plus Lenalidomide in Diffuse Large B Cell Lymphoma for Patients of 80 Years or older.
J Clin Oncol . 2021 Apr 10;39(11):1203-1213. doi: 10.1200/JCO.20.02666.
Learn more
Lysa
2021_LYSA_A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the “REal world dAta in LYmphoma and survival in adults” (REALYSA) cohort
BMC Public Health . 2021 Mar 2;21(1):432. doi: 10.1186/s12889-021-10433-4.
Learn more
Lysa
2021_LYSA_Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lyphoma: a phase 1/2 trial
Blood . 2021 Feb 18;137(7):877-887. doi: 10.1182/blood.2020008727.
Learn more
Lysa
2021_LYSA_BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres
Br J Haematol . 2021 Feb;192(3):e94-e98. doi: 10.1111/bjh.17279.
Learn more
Lysa
2021_LYSA_Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma
Blood Adv . 2021 Jan 26;5(2):539-548. doi: 10.1182/bloodadvances.2020003081.
Learn more
Lysa
2021_LYSA_Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial
Leukemia . 2021 Jan;35(1):143-155. doi: 10.1038/s41375-020-0838-5
Learn more
Lysa
2021_LYSA_Combining Brentuximab Vedotin With Dexamethasone, High-Dose Cytarabine and Cisplatin as Salvage Treatment in Relapsed or Refractory Hodgkin Lymphoma: The Phase II HOVON/LLPC Transplant BRaVE Study
Haematologica . 2021 Apr 1;106(4):1129-1137.
Learn more